Biology subjects

DiLeone, R.

Publications and source records attributed to DiLeone, R..

4 recordsLinked to original sources

bioRxiv2026

The selective OX1R antagonist 1-SORA-51 reduces binge-like feeding behavior in male and female mice without detectable changes in dopamine.

Binge eating disorder (BED) is characterized by episodic overconsumption of palatable food and involves dysregulated motivational and arousal processes. The orexin (hypocretin) system, through its widespread projections to mesolimbic circuits, has been implicated in cue-driven reward seeking and escalated intake, raising the possibility that orexin receptor antagonists may modulate binge-like behavior. Here we evaluated the effects of a dual orexin receptor antagonist (DORA-22) and an OX1R-selective antagonist (1-SORA-51) in a cyclic intermittent high-fat access model that generates robust and reproducible binge-like intake in male and female mice. DORA-22 produced no detectable effect on consumption at either early (2 h) or extended (24 h) binge timepoints. In contrast, 1-SORA-51 significantly reduced high-fat intake during the initial 2 hours of access in both sexes, with no effect on 24-hour consumption, indicating a selective attenuation of the early phase of binge intake. Fiber photometry recordings of GRABDA2m fluorescence in the nucleus accumbens revealed that 1-SORA-51 did not alter baseline dopamine signals or the dopamine increase triggered by high-fat pellet delivery, demonstrating that its behavioral effects occur without detectable modulation of mesolimbic dopamine dynamics. Together, these findings identify OX1R antagonism as a strategy for suppressing the initiation of binge-like feeding and highlight the receptor-level specificity of orexin contributions to maladaptive overconsumption.

neuroscience↗

bioRxiv2025

The GLP-1R Agonist Semaglutide Reduces Motivated Running and Alters Dopamine Dynamics in the Nucleus Accumbens

Glucagon-like peptide-1 receptor (GLP-1R) agonists have recently emerged as powerful tools for the treatment of obesity through their ability to suppress food intake. However, their effects on non-ingestive motivated behaviors remain incompletely understood. Here, we show that the long-acting GLP-1R agonist semaglutide (SG) suppresses voluntary wheel running in both lean and diet-induced obese mice. Importantly, this suppression of activity was not caused by hypophagia and was accompanied by decreased motivation, with SG-treated mice displaying reduced effort for wheel access in a progressive ratio task. Real-time measurements of dopamine via fiber photometry revealed specific dopamine changes in the nucleus accumbens at both the beginning and end of running bouts, with SG-treated animals showing amplified dopamine dynamics at these key behavioral timepoints. Collectively, these data reveal important non-ingestive behavioral effects of GLP-1R agonism and suggest a role for dopamine circuits in mediating reductions of volitional activity following SG treatment.

neuroscience↗

bioRxiv2024

Sex differences in oxycodone-taking behaviors are linked to disruptions in reward-guided, decision-making functions

Problematic opioid use that emerges in a subset of individuals may be due to pre-existing disruptions in the biobehavioral mechanisms that regulate drug use. The identity of these mechanisms is not known, but emerging evidence suggests that suboptimal decision-making that is observable prior to drug use may contribute to the pathology of addiction and, notably, serve as a powerful phenotype for interrogating biologically based differences in opiate-taking behaviors. The current study investigated the relationship between decision-making phenotypes and opioid-taking behaviors in male and female Long Evans rats. Adaptive decision-making processes were assessed using a probabilistic reversal-learning task and oxycodone- (or vehicle, as a control) taking behaviors assessed for 32 days using a saccharin fading procedure that promoted dynamic intake of oxycodone. Tests of motivation, extinction, and reinstatement were also performed. Computational analyses of decision-making and opioid-taking behaviors revealed that attenuated reward-guided decision-making was associated with greater self-administration of oxycodone and addiction-relevant behaviors. Moreover, pre-existing impairments in reward-guided decision-making observed in female rats was associated with greater oxycodone use and addiction-relevant behaviors when compared to males. These results provide new insights into the biobehavioral mechanisms that regulate opiate-taking behaviors and offer a novel phenotypic approach for interrogating sex differences in addiction susceptibility and opioid use disorders.

neuroscience↗

bioRxiv2019

Orexin signaling in GABAergic lateral habenula neurons modulates aggressive behavior

Heightened aggression is characteristic of multiple neuropsychiatric disorders and can have a wide variety of negative effects on patients, their families, and the public. Recent studies in humans and animals have implicated brain reward circuits in aggression and suggest that, in subsets of aggressive individuals, repeated domination of subordinate social targets is reinforcing. Here, we show that orexin neurons originating from the lateral hypothalamus activate a small population of GABAergic interneurons in the lateral habenula (LHb) via orexin receptor 2 (OxR2) to promote aggression and conditioned place preference (CPP) for aggression-paired contexts. Our study suggests that the orexin system is a potential target for the development of novel therapies aimed at reducing aggressive behaviors and provides the first functional evidence of a local inhibitory circuit within the LHb.

neuroscience↗